Ublituximab Recruiting Phase 2 Trials for Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) / CLL Progression Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04149821Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy